Burzotta F, Di Castelnuovo A, Amore C, D'Orazio A, Di Bitondo R, Donati M B, Iacoviello L
Istituto di Ricerche Farmacologiche Mario Negri, Department of Vascular Medicine and Pharmacology, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy.
Thromb Haemost. 1998 Feb;79(2):354-8.
The PAI-1 gene promoter 4G/5G polymorphism was found to be associated with plasma PAI-1 activity in Northern and Central Europe populations, but no data are available on the association between this polymorphism and PAI-1 levels in Southern Europe countries (such as Italy) where the incidence of ischemic disorders is lower. This study shows that among populations with different incidence of atherothrombotic disorders the 4G/5G PAI-1 gene promoter polymorphism has the same importance in the regulation of plasma PAI-1 activity. Moreover, we have analysed some gene-environmental interactions: the correlation between PAI-1 and cholesterol in non dyslipidemic subjects and the correlation between PAI-1 activity and tryglicerides in dyslipidemic subjects differed according to the 4G/5G genotype class. Thus, our findings suggest that, among subjects with or without metabolic disorders such as dyslipidemia, completely different gene-environment interactions may occur.
在北欧和中欧人群中，已发现纤溶酶原激活物抑制剂-1（PAI-1）基因启动子4G/5G多态性与血浆PAI-1活性相关，但在缺血性疾病发病率较低的南欧国家（如意大利），关于这种多态性与PAI-1水平之间的关联尚无数据。本研究表明，在动脉粥样硬化血栓形成性疾病发病率不同的人群中，4G/5G PAI-1基因启动子多态性在调节血浆PAI-1活性方面具有相同的重要性。此外，我们分析了一些基因-环境相互作用：非血脂异常受试者中PAI-1与胆固醇之间的相关性以及血脂异常受试者中PAI-1活性与甘油三酯之间的相关性根据4G/5G基因型类别而有所不同。因此，我们的研究结果表明，在有或没有血脂异常等代谢紊乱的受试者中，可能会出现完全不同的基因-环境相互作用。
